Novartis nabs EU clearance for Jetrea; Roche's hep C drug Pegasys wins new use

Novartis ($NVS) won European approval for its eye drug Jetrea, as a treatment for vitreomacular traction, which can cause progressive and irreversible vision loss. The European Medicines Agency also approved a new use for Roche's ($RHHBY) hepatitis C drug Pegasys, in children and adolescents aged 5 years and older. Release | Release